X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs BIOCON LTD - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. BIOCON LTD WOCKHARDT LTD./
BIOCON LTD
 
P/E (TTM) x -22.0 92.4 - View Chart
P/BV x 2.2 7.8 28.5% View Chart
Dividend Yield % 0.0 0.1 1.2%  

Financials

 WOCKHARDT LTD.   BIOCON LTD
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
BIOCON LTD
Mar-18
WOCKHARDT LTD./
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,0121,188 85.2%   
Low Rs532305 174.3%   
Sales per share (Unadj.) Rs355.968.7 517.8%  
Earnings per share (Unadj.) Rs-60.37.6 -798.2%  
Cash flow per share (Unadj.) Rs-46.814.0 -334.7%  
Dividends per share (Unadj.) Rs0.011.00 1.0%  
Dividend yield (eoy) %00.1 1.0%  
Book value per share (Unadj.) Rs257.886.3 298.6%  
Shares outstanding (eoy) m110.63600.00 18.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.210.9 20.0%   
Avg P/E ratio x-12.898.9 -13.0%  
P/CF ratio (eoy) x-16.553.4 -30.9%  
Price / Book Value ratio x3.08.6 34.6%  
Dividend payout %013.2 -0.1%   
Avg Mkt Cap Rs m85,379447,900 19.1%   
No. of employees `0006.36.1 101.7%   
Total wages/salary Rs m9,3719,311 100.6%   
Avg. sales/employee Rs Th6,295.06,705.8 93.9%   
Avg. wages/employee Rs Th1,498.31,514.2 99.0%   
Avg. net profit/employee Rs Th-1,066.3736.9 -144.7%   
INCOME DATA
Net Sales Rs m39,36941,234 95.5%  
Other income Rs m1,2022,062 58.3%   
Total revenues Rs m40,57143,296 93.7%   
Gross profit Rs m188,291 0.2%  
Depreciation Rs m1,4953,851 38.8%   
Interest Rs m2,555615 415.4%   
Profit before tax Rs m-2,8305,887 -48.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2571,569 16.4%   
Profit after tax Rs m-6,6694,531 -147.2%  
Gross profit margin %020.1 0.2%  
Effective tax rate %-9.126.7 -34.1%   
Net profit margin %-16.911.0 -154.1%  
BALANCE SHEET DATA
Current assets Rs m33,79641,486 81.5%   
Current liabilities Rs m26,91721,413 125.7%   
Net working cap to sales %17.548.7 35.9%  
Current ratio x1.31.9 64.8%  
Inventory Days Days7964 124.0%  
Debtors Days Days8994 94.7%  
Net fixed assets Rs m39,66450,661 78.3%   
Share capital Rs m5533,000 18.4%   
"Free" reserves Rs m27,96848,808 57.3%   
Net worth Rs m28,52251,808 55.1%   
Long term debt Rs m21,73117,898 121.4%   
Total assets Rs m81,62099,897 81.7%  
Interest coverage x-0.110.6 -1.0%   
Debt to equity ratio x0.80.3 220.5%  
Sales to assets ratio x0.50.4 116.9%   
Return on assets %-5.05.2 -97.8%  
Return on equity %-23.48.7 -267.3%  
Return on capital %-7.79.6 -79.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80712,058 81.3%   
Fx outflow Rs m1,7897,348 24.3%   
Net fx Rs m8,0194,710 170.2%   
CASH FLOW
From Operations Rs m6846,621 10.3%  
From Investments Rs m6,302-6,840 -92.1%  
From Financial Activity Rs m-7,695-2,397 321.0%  
Net Cashflow Rs m-664-2,612 25.4%  

Share Holding

Indian Promoters % 74.5 40.4 184.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 2.3 8.4 27.4%  
FIIs % 7.7 10.7 72.0%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 19.9 77.4%  
Shareholders   67,757 109,995 61.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Sep 21, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS